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1. INTRODUCTION 
           Pulmonary aspiration of gastric contents in patients undergoing 
surgical procedures under General anesthesia still remains one of the 
common intra operative complications. This carries even more greater 
significance in emergency scenarios where the preoperative fasting 
guidelines are not met with. The obstetric subset of patients still carries even 
more increased risk of pulmonary aspiration, since they have delayed gastric 
emptying time and reduced LES tone and hence, they are considered always 
as full stomach.  
 
In UK, the recent maternal mortality auditing report shows that, 
majority of deaths resulting from anesthetic events in the peri-operative 
period are found to be associated at the time of induction of general 
anesthesia. This is thought to result from two major causes, inhalation of 
gastric contents (aspiration) and failure to intubate the trachea, resulting in 
cardiac arrest.
 
Aspiration occurs in 1 in every 3000 cases of anaesthesia and 
accounts for 10% - 30% of the deaths related with anaesthesia. Studies 
regarding perioperative aspiration in general surgical population in US 
shows incidence of 1/3216, morbidity of 1/ 16576 & mortality of 1/71829 
3
.  
        As it has been shown that acid aspiration causes chemical pneumonitis, 
various methods are used to reduce the pH and volume of the stomach 
contents 
[1]
.  
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Particulate antacids, e.g Aluminium hydroxide and Magnesium trisilicate, 
were used until they themselves were implicated in causing a chemical 
reaction in the lungs of animals 
[1]
. Hence, particulate antacids should be 
avoided in the perioperative setting.  This led to the use of non-particulate 
antacids. Of all the non particulate antacids, the most popular is 0.3 mol 
sodium citrate. This drug is specially useful in neutralizing of gastric acid 
especially during emergency surgical procedures under general anesthesia.  
      
The risk of pulmonary aspiration is severe when the gastric content 
has a pH< 2.5 and a volume > 25ml. It has been proven that, when 
administered as a single dose before the induction of anesthesia 0.3 molar 
sodium citrate is effective in elevating gastric pH above 3.5 in all patients
2
. 
The risk of acid pneumonitis should aspiration occur, would therefore be 
minimized. In Indian scenarios, not much of studies or reviews are there 
regarding the administration and efficacy of sodium citrate as antacid 
prophylaxis.  
 
Hence this study was carried out with an aim to establish the efficacy 
and to encourage the routine use of 0.3 molar sodium citrate, especially  in 
the obstetric population. In this study, pH of gastric content samples before 
and after sodium citrate administration are measured with aid of a digital pH 
meter and is used to determine the efficacy of 0.3M sodium citrate. 
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2. PHYSIOLOGY OF GASTRIC ACID SECRETION 
Food is generally presented to the stomach in small soft boluses, 
prepared in the mouth by chewing and moistened by saliva, containing 
mucins and ptyalin. As a result of its large capacity, the stomach is capable 
of accommodating a significant quantity of food without a large increase in 
intragastric pressure. Its main function is to maintain an environment where 
its digestive enzymes can commence protein digestion and to move food at 
a controlled rate via the pyloric sphincter into the duodenum. The major 
issues for gastric physiology are the nature and control of gastric secretion 
and the methods of controlling motility and gastric emptying. Not 
surprisingly, the system is integrated with considerable overlap in control of 
both functions. 
Gastric secretion: 
        Normal volume of gastric secretion is 2–3 L/day . There are three types 
of cells: 
1. Chief or peptic cells in the antrum, which secrete proteolytic proenzymes 
called pepsinogens. To avoid cellular damage, they are inactive until 
they enter the gastric lumen, where in the acid pH they are cleaved to 
form active pepsins that hydrolyse proteins. 
2. Parietal cells, which secrete hydrochloric acid and intrinsic factor. The 
latter is important for the absorption of vitamin B12 in the terminal 
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ileum. Hydrochloric acid secretion requires the production of H2CO3 in 
the cell interior, catalysed by carbonic anhydrase. The secretion of H+ is 
an active process involving a proton pump working against a 3 million-
fold concentration gradient between the cell and gastric lumen and in 
which K+ is exchanged. It produces a gastric pH of between 1 and 3, 
which kills bacteria, allows the activation of pepsin, and is optimum for 
its function (active at pH < 3.5). As acid secretion increases after eating, 
it is accompanied by an increase in pH of gastric venous blood (alkaline 
tide), with bicarbonate entering the blood in active exchange for chloride 
ion. This is mirrored, however, by bicarbonate secretion in pancreatic 
juices such that the body pH remains stable. 
3. Mucous cells, which secrete mucin. This secretion is alkaline, has a 
protective role for mucosal cells, and may lubricate the gastric lumen. 
Inhibition of prostaglandin function disrupts mucin production, leaving 
gastric cells vulnerable to gastric acids. 
   
 
 
 
 
Secretions pH 
Saliva 6-7 
Gastric fluid 1.0-3.5 
Bile 7-8 
Pancreatic fluid  8.0-8.3 
Small intestine 6.5-7.5 
Colon 7.5-8.0 
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3. GASTRIC pH  ANALYSIS
30
 
 
The pH of a substance is a measure of its hydrogen ion activity which 
determines whether it is acidic, neutral or alkaline. 
 
Methods – Various methods have been used in measuring the pH of 
body fluids. 
 
1. Litmus Paper 
           Litmus paper is a small strip of specially chemical impregnated 
paper. The paper strip is made by dipping and treating it in a combination of 
dyes. So, while these strips are used for testing, the dyes change color 
according to the pH of the medium in which they are tested in. On testing 
the paper in Acidic liquids with a pH of less than 7, the paper turns red.  
Alkaline liquids (pH more than 7) change it to blue or purple. Litmus paper 
strips are used for estimating the relative pH of liquids roughly, but it does 
not indicate accurate values.  Method - Measurement is made by briefly 
dipping the end of an unused strip in the testing liquid and allowing it to 
dry. The color change is then noted based on the acidity or alkalinity.  
 
2. Field Kit 
A field kit consists of a empty, clean container into which a sample 
liquid is placed, and a bottle of indicator solution. A few drops of the 
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indicator solution are placed in the sample, and the pH is determined by the 
change in color of the liquid. Because different indicator solutions perform 
better at certain pH levels, a variety of kits is available for different ranges. 
The accuracy of the field kit depends on the narrowness of the indicator 
solution's range. 
 
3. Probe and Meter 
This is the most accurate and widely used common means of 
measuring pH. In this method, the pH is measured by a lab device called a 
probe and meter, otherwise called, a pH meter. The probe consists of a 
electrode made of glass, through which a small voltage is passed. The meter, 
a voltmeter, measures the electronic impedance across the glass electrode 
and displays pH in terms of units, by conversion of volts. Measurement is 
made by submerging the probe in the liquid till the mark given, until a 
reading is registered by the meter.  A pH meter has to be calibrated with two 
standard liquid solutions of known pH before testing the liquid every time.  
As this method needs large volumes of 40-50ml of gastric aspirate, its 
routine clinical use is not always feasible. 
 
4. Digital pH meters: 
        Digital pH meters are used for measuring and display of the pH of 
liquids and semi-solids. In this type of digital pH meters, a probe is 
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incorporated that reacts with the liquid being measured. Then, the internal 
electronics to read the output signals from the probe and it displays the 
result. These meters are more reliable and accurate than the other types like 
test strips or liquid reagents. As this requires only15-20ml of gastric aspirate 
and the results are displayed instantaneously, this method has been used 
widely. Moreover it is of cheaper cost, portable, easily available. 
 
Other non-invasive methods in common are by using electrical 
impedance tomography and pH sensitive radio telemetric capsule.                                           
 
 The pH meter used in this study for evaluating the pH of gastric 
aspirate is a hand held pen like digital PH meter shown below An useful 
instrument to perform quick pH measurements - simply remove the black 
protective cap (shown below), switch on and dip the probe into the liquid to 
be tested and pH value is indicated in form of the LCD digital display. The 
reading is calibrated with the buffer solutions, whose pH is known. 
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Picture of Digital pH meter 
Model : Hanna HI-96106 Champ pH Tester- used in our study. 
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4. PHYSIOLOGY OF NAUSEA AND VOMITTING 
 
Nausea is an unpleasant subjective sensation of impending vomiting 
and is sometimes associated with epigastric discomfort. Vomiting is an 
active process under the control of the vomiting centre, and involves the 
active muscular expulsion of stomach contents in a reflex that, like 
swallowing, involves carefully timed respiratory and peristaltic responses. 
 
The vomiting centre lies in the dorsal part of the lateral reticular 
formation in the medulla oblongata of the brainstem. It receives inputs from 
a variety of sources, including the cerebral cortex, which can produce 
vomiting associated with emotion and unpleasant somatic sensations. The 
predominant receptor types are dopamine, serotonin (5-HT3), and 
acetylcholine. The chemoreceptor trigger zone (CTZ) is located in what is 
known as the area postrema in the floor of the fourth ventricle and relays to 
the vomiting centre. It represents the major area of input into the vomiting 
centre. Lying outside the bloodbrain barrier, it is sensitive to chemical 
stimuli from drugs such as opioids and bloodborne toxins. The most 
prevalent receptor subtypes in the CTZ are dopamine, acetylcholine, and 
serotonin.  
 
The act of vomiting, initiated by the vomiting centre, involves 
integration of respiratory, peristaltic and vascular reflexes involving a 
10 
 
number of cranial nerves (5th, 9th, 10th, and llth) and spinal nerves 
supplying the abdominal musculature. It is often preceded by pallor, 
increased heart rate, salivation, and sweating. A deep inspiration 
accompanies closure of the glottis and inhibition of further respiration. 
Descent of the diaphragm and repeated contraction of abdominal muscles 
raises intragastric pressure, and retrograde contractions of the stomach and 
small intestine force gastric contents into the oesophagus as the lower 
oesophageal sphincter relaxes. This retching manoeuvre precedes relaxation 
of the upper oesophageal sphincter, which allows food to be expelled in the 
act of vomiting. 
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PULMONARY ASPIRATION IN THE PERIOPERATIVE 
SCENARIO 
 
Pulmonary aspiration of gastric contents is considered to be one  of 
the most dreaded and worst  complications of anesthesia.  Pulmonary 
aspiration is defined as a constellation of clinical features resulting from  the 
inhalation by the patient or the passive introduction  of oropharyngeal or 
gastric contents into the larynx and lower respiratory tract.
5
  Prevention of 
aspiration by identification of patients at risk, preoperative fasting,  drug 
treatment and  various anesthetic  maneuvers are cornerstones of safe 
anesthetic practice.   
12 
 
5. PATHOPHYSIOLOGY OF PULMONARY ASPIRATION 
 
When gastric contents get aspirated into the lungs, the resultant 
pulmonary damage will manifest based on the quantity and quality of the 
contents aspirated. The pulmonary reactive injury after gastric aspiration 
comes under 3 groups:  
 
1. Particle related, 
2. Acid related  
3. Bacterial 8.  
 
Pathophysiology of Aspiration
4 
1. Aspiration of particulate matter : 
Obstruction of airway due to edema 
Acute inflammation 
Granuloma formation 
2. Aspiration of acid : 
Infiltration of neutrophils at that site 
Pulmonary edema 
Damage to alveolar mucosa 
Depletion of type I pneumocytes 
Reduced surfactant and alveolar collapse  
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3. Alveolar-capillary membrane disruption 
4. Fluid leakage from capillaries in pulmonary bed 
5. Bacterial infection- due to translocation of organisms from 
oropharyngeal secretions 
 
Food particles which are very miniscule that they enter the distal 
airway to initiate a foreign body reaction characterized by acute or subacute 
inflammation and eventually formation of granuloma in chronic period.  The 
aspiration of particulate antacids like aluminium or magnesium hydroxides 
produces an adverse reaction similar to the above
9
. 
 
A study by Kennedy et.al in rats showed a biphasic pattern of 
pulmonary mucosa injury after aspiration of acid. 
3
 The peak in the phase 
one occurs at around 1-2 hrs after aspiration and it is due to the direct, 
caustic nature of the gastric contents and a low pH of the aspirated contents 
on the alveolar–capillary cells.  The second phase, which peaks at 4-6 hours, 
is caused due to the inflammatory infiltration of polymorphic cells, across 
the alveolar barrier into the alveolar space and  into the interstitial area , 
suggesting  features of  acute inflammation.  
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MECHANISM OF BRONCHOALVEOLAR INJURY : 
 
The mechanisms proposed  by which the pulmonary  injury occurs 
after gastric aspiration, has been mediated by a variety of numerous  
inflammatory cells, inflammatory mediators, cellular adhesion factors. It is 
also aided by an array of  enzymes cyclooxygenase , Tumor Necrosis 
Factor- alpha,  interleukin – 6, 8, and lipoxygenase  enzyme products, and 
various  reactive oxygen species.
11
  
 
RISK FACTORS FOR PULMONARY ASPIRATION 
4
 :  
 
Patients likely to have gastric contents of increased volume or acidity, 
elevated intragastric pressure, or decreased tone of the lower esophageal 
sphincter (LES) are considered to be at increased risk for perioperative 
pulmonary aspiration. These
 
patients have dysphagia due to neurological 
causes, gastroesophageal sphincter incompetency, or anatomical 
abnormalities of the upper alimentary tract. The risk is  higher  in elderly 
persons (dysphagia & gastroesophageal reflux). Also, in old age there is 
poor oral care, resulting in colonization by pathogens, including  
Pseudomonas aeruginosa, and Staphylococcus aureus. In 40-70% patients 
with stroke,“silent aspiration” occurs.  
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1. Regurgitation or vomiting  
During the period of  hypotension 
Increased intragastric volume and pressure 
Decreased lower esophageal barrier pressure 
Lower esophageal sphincter incompetency 
2. Incompetent and ineffective  protective reflexes of the larynx  
Neurological disorders (lower cranial nerves palsy) 
Depressants of the Central nervous system 
Neuromuscular causes and myopathies 
Debilitaed patients and critically ill. 
Elderly patients due to debility or advanced age(obtunded airway 
reflexes) 
 
Among this, the pregnant patient is at increased risk of aspiration 
because of increased frequency of gastro-oesophageal reflux and delayed 
gastric motility and gastric emptying 
5, 6
.  
 
DETERMINANTS OF MORBIDITY: 
 
The main factors which play a role in morbidity are the critical 
volume and pH of gastric contents and the type of particulate content in the 
aspirate. 
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1. CRITICAL VOLUME AND pH : 
 
Initial stages of experimental studies in animals by Teabeaut  
emphasized the importance of the pH of the gastric contents aspirated, the 
severity of pneumonitis being related to increased acidity of aspirate . 
Subsequently, Roberts and Shirley
5
 "arbitrarily defined the patient at risk of 
aspiration as that patient with at least 25 mL of gastric juice of pH below 2.5 
in the stomach at delivery" . A further study by James et al. demonstrates 
mortality rate of 90% in rats after aspiration of gastric contents, 0.4 mL kg-' 
at pH of 1.0.  
 
Later studies by Rocke D A et al, suggests enough evidence to change 
the "at risk" criteria to a pH less than 3.5 and gastric volume of more than 
50 mL. They also tell that by using newer critical value criteria, it will allow 
us to focus less on attempts at targeting to get small residual gastric volumes 
and focus  more on pH correction through H2  blockers and antacids. 
 
2. PARTICULATE MATTER :      
 
The volume and acidity of aspirated gastric contents are not 
considered the only determinants of the clinical sequel  when gastric 
contents get aspirated into the  trachea. Since the analysis of studies by  
Bond and coworkers, it has been emphazised  that  aspiration of gastric fluid 
containing particulate antacids  can cause  severe aspiration pneumonitis,  
17 
 
even when pH is at near  7.0.  It can present pulmonary edema  and 
hypoxemia requiring mechanical ventilatory support in the immediate 
postoperative period 
 
CLINICAL FEATURES : 
 
Patients who have aspirated the gastric might manifest with various 
signs and symptoms.  Most of  the  patients in this group  present with only  
cough or an inspiratory wheeze, and some persons may have what is called 
as a „silent aspiration‟. It presents as a arterial hypoxia and desaturation 
along with radiologic features of aspiration.   
 
In the most extreme cases, they might present with intense wheezing 
with bilateral rales, severe cough, shortness of breath (dyspnea). Sinus 
tachycardia, cyanosis, hypoxemia and pulmonary edema, hypotension. 
Finally, there is a rapid progression to severe acute respiratory distress 
syndrome and death ensues.
12
 
 
Warner et.al did an analysis on 67 patients who got accidentally 
aspirated while under anesthesia.
3 
Among these, forty two (63%) patients 
had no features of aspiration. Among the remaining twenty five who 
manifested symptoms, 13 patients were given mechanical ventilatory 
support for more than 6 hours duration. Four patients succumbed to death. 
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DIAGNOSIS OF PULMONARY ASPIRATION: 
 
Asymptomatic aspiration of gastric contents can occur during sleep in 
45% of individual and in 70 % persons who are unconscious. The risk factor 
even more goes up in obese, obstructive sleep apnea and in pregnancy. 
Clinical signs like dyspnea, tachycardia, low grade fever, wheezing, diffuse 
rales suggest aspiration
13
. 
 
A chest radiograph can be useful in diagnosing aspiration 
pneumonitis; however, in patients who aspirate and have an uncomplicated 
clinical course, 8% may have normal chest radiographs throughout their 
hospitalization. In almost one third of aspiration cases, the initial chest 
radiograph does not represent the full extent of lung involvement, and the 
findings on the chest film will worsen before improvement is seen. 
 
No particular distribution of lung injury on the chest radiograph is 
diagnostic of aspiration pneumonitis. Both the right and left lungs may be 
affected, and any lobe of the lungs may be involved. Likewise, the 
characteristics of the infiltrates noted on the chest film are not diagnostic. 
Small, irregular lung infiltrates are generally observed; however, mixed 
infiltrates are seen and may be misinterpreted as acute processes 
superimposed upon chronic processes, or even as two distinct disease 
processes. 
19 
 
The earliest clinical findings reflective of the pulmonary aspiration of 
gastric contents are those of altered pulmonary function. Following 
aspiration, reflex laryngospasm and bronchospasm result because of 
chemical and physical irritation of the airways. Surfactant activity decreases 
with the ensuing rapid development of airway and alveolar injury and fluid 
exudation. Intrapulmonary shunting develops, and hypoxemia results. With 
increasing damage to lung tissue, lung compliance decreases.Invasive 
investigations may confirm aspiration, such as  broncho alveolar lavage, 
fiberoptic bronchoscopy. 
 
Fiberoptic bronchoscopy is considered the gold standard for 
diagnosing a suspected case of aspiration. Broncho alveolar lavage and 
protected brush specimen are useful diagnosing ceses of nosocomial 
pneumonia. Less invasive methods like chest X-ray and radio scintigraphy 
are also helpful.  
 
Percutaneous needle aspiration and open lung biopsy offer definitive 
diagnosis but are associated with high complication rates. Bronchoscopy 
examination after aspiration shows erythematous changes at the major 
bronchial carina 
18
. Diffuse infiltrates or consolidation of dependent 
pulmonary segments is seen in the radiography.  
20 
 
Radiographically visible
14
 infiltrates are almost evident within several 
hours and resolves by the next 48-72 hours. An increasing intensity of the 
infiltrates denotes super added infection or retained secretions. Foreign body 
aspiration in children can be diagnosed by ventilation –perfusion imaging.  
 
The radiographic evidence of an infiltrate in specific 
bronchopulmonary segment can vary depending on the patient position. In 
patients in recumbent position, the posterior segment of upper lobes and the 
apical segment of lower lobes are commonly involved, whereas in patients 
who aspirate in semirecumbent or upright position, the basal segments of 
lower lobes are affected.  
 
Thus in short, unless the aspiration event is witnessed or the tracheal 
suction yields gastric contents or enteral feeds, no modality is confirmatory 
for diagnosing a case of aspiration. 
 
SEQUELAE OF PULMONARY ASPIRATION: 
 
1. Aspiration pneumonitis 
2. Aspiration pnumonia. 
3. Community acquired pneumonia. 
4. Acute Respiratory Distress Syndrome. 
5. Pulmonary edema.                                                                      
21 
 
                                 
 
 
 
 
 
 
 
 
Anteroposterior Radiograph of the Chest, Showing Air-Space 
Consolidation (Arrows) in the Right Lower Lobe- suggestive of 
aspiration pneumonitis. 
 
DIFFERENTIATING ASPIRATION PNEMUONITIS AND 
ASPIRATION  PNEUMONIA :  
 
Aspiration pneumonitis also well known by the term Mendelson‟s 
syndrome  is a chemical induced injury of the pulmonary mucosa  caused by 
the inhalation of sterile gastric contents which is acidic in nature. 
 
Aspiration pneumonia is an infectious process caused by the 
inhalation of oropharyngeal secretions that are colonized by pathogenic 
bacteria. 
22 
 
Pulmonary aspiration of pharyngeal liquids is fairly common and 
usually is without sequelae.
13
 However, when this aspiration exceeds a 
certain frequency or volume (as mentioned above) and contains pathogenic 
organisms, aspiration pneumonia results. Aspiration pneumonia is not to be 
confused with aspiration pneumonitis, which results from chemically 
induced damage to lung tissue. Aspiration pneumonia is caused by a 
bacterial infection and is the cause of at least 10% of community-acquired 
pneumonias.
16
The infective organisms are Pseudomonas sp, Enterobacter 
sp, Klebsiella sp, Actinobacter sp, and methacillin-resistant Staphylococcus 
aureus. 
 
MANAGEMENT OF PULMONARY ASPIRATION : 
Aspiration Pneumonitis: 
The upper airway including the oropharynx and hypopharynx needs 
to be thoroughly suctioned after a witnessed aspiration. Endotracheal 
intubation is considered as a protection for patients who are unable to 
protect their airway from secretions
16
. Antibiotic therapy should be 
considered for patients with aspiration pneumonitis failing to clear within 
next 48 hours after aspiration
17
. Empirical antibiotics coverage is 
appropriate for patients who aspirate gastric contents and in patients with 
small intestinal obstruction or other causes which may be associated with 
23 
 
bacterial colonization in stomach. In this case, the sterile gastric contents 
become infective
17
.  
Steroids have been in use since a long time for the management of 
aspiration pneumonitis. But, on the other hand some of the controlled trials 
on steroids did not demonstrate a special benefit of high-dose 
corticosteroids in patients with the acute respiratory distress syndrome. This 
implies that the administration of corticosteroids cannot be routinely 
recommended in all patients with aspiration.
18
 
 
Aspiration Pneumonia: 
 
Antibiotic therapy is indicated in patients with aspiration pneumonia. 
The choice of antibiotics should depend on the setting in which the 
aspiration occurs as well as the patient‟s medical and surgical comorbid 
illness. However, when indicated antibiotic agents acting against gram-
negative spectrum like fluoroquinolones, third-generation cephalosporins, 
and piperacillin are used
16,17
.  
 
PREVENTION OF ASPIRATION:  
GENERAL MEASURES:  
Because diagnosis and treatment may be quite difficult, prevention of 
aspiration pneumonitis is important. When intubation is required, the 
duration of intubation and ventilation must be as brief as clinically possible. 
24 
 
Airway contamination should be minimized, and suctioning of the airway 
must be conducted in a sterile manner. Antibiotic use should be minimized 
to reduce the emergence of resistant strains. When tube feeding is 
administered, gastric distension is avoided. Good oral hygiene is necessary, 
and patients should be maintained in a semierect position (≥30 degrees), 
with the head of bed elevated whenever possible to reduce passive 
regurgitation 
19
. 
 
Methods
22 
to Reduce Risk of Regurgitation and Pulmonary Aspiration 
1. Minimize Intake 
a. Adequatepreoperative fasting 
b. Clear liquids only if necessary  
2. Increase gastric emptying 
Prokinetics (e.g., metoclopramide)  
3. Reduce gastric volume and acidity 
a. Nasogastric tube aspiration 
b. Nonparticulate antacid (e.g.,0.3.M sodium citrate) 
c. H2-receptor antagonists (e.g., ranitidine) 
4. Airway management and protection during anesthetic induction and 
intubation : 
a. Cricoid pressure( Sellick‟s maneuver) 
b. Cuffed endotracheal intubation- provides better airway seal 
25 
 
c. ProSeal laryngeal mask airway- it has got a gastric drainage port 
and the cuff provides better seal when compared to classic LMA 
 
1. PREOPERATIVE FASTING GUIDELINES FOR ELECTIVE 
SURGERY- ASA- 2011
20 :
 
Food Material  Minimum Fasting Period required  
Clear liquids   2 hours 
Breast milk    4 hours 
Nonhuman milk   6 hours 
Infant formula   6 hours 
Light meal    6 hours 
Fatty, heavy meals   8 hours 
 
These recommendations, as given in American Society of 
Anesthesiologists- Fasting guidelines 2011, are applicable in all healthy 
patients posted for elective surgical procedures.  
 
2. PREINDUCTION NASOGASTRIC TUBE ASPIRATION : 
 
When a patient who is at increased risk for periop aspiration comes 
for surgery, the stomach can be emptied, by introducing and suctioning 
through an orogastric or a nasogastric (NG) tube
4
.But, the presence of a 
gastric tube interferes with the integrity and function of the lower 
esophageal sphincter of the gastroesophageal junction and this is going to 
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augment the gastro esophageal reflux by its action as a “wick.”21 Further, 
the presence of a foreign body (nasogastric tube) in the pharynx could also 
interfere with laryngoscopy. These considerations supports the removal of 
the gastric tube before induction. 
 
Hardy and colleagues
 
did a study in 24 patients, by measuring the 
volume of gastric contents aspirated through an 18 F Salem Sump tube, then 
came to a conclusion “that the amount of aspirated gastric fluid… is a very 
reliable estimate of the volume of contents present in the stomach during the 
time of induction” and that suctioning in the naso gastric tube “could also be 
an effective method to empty the liquid contents of the stomach, prior to 
giving anaesthesia.” 
 
3. CRICOID PRESSURE : 
 
It is given during anaesthetic induction and intubation. As described 
by Sellick
[23]
 in 1961, “this maneuver results in  the temporary passive 
occlusion of the upper end of the oesophagus by giving  backward pressure 
of the cricoid cartilage(the only cartilage in the larynx which forms a 
complete ring),  against the bodies of the cervical vertebrae. Extension of 
the neck and applying pressure over the cricoid cartilage obliterates the 
oesophageal lumen at the level of the body of the fifth cervical vertebra. 
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This occlusive force or pressure is maintained until intubation of trachea and 
inflation of the cuff of the endotracheal tube is completed.”   
 
By following this maneuver , the lumen of the esophagus is nearly 
occluded, but the patency of tracheal lumen is maintained by the completely 
circular nature of the cricoid cartilage.
22
 Early cadaveric studies showed that 
correctly applied cricoid pressure was effective in preventing gastric fluids 
under 100 cm H2O pressure from leaking into the pharynx, thus preventing 
aspiration
22
. 
 
4. PHARMACOLOGICAL METHODS OF REDUCING THE 
GASTRIC VOLUME AND ACIDITY
4 : 
An wide and impressive range of pharmacologic interventions are 
now implicated in  promoting gastric emptying, inhibit GER, and reduce the 
acid content of gastric fluids. These drugs have been in use since a long time 
with an established record of safety and helps in converting the more acidic 
gastric fluid to less damaging to the lungs. However, because of the limited 
incidence of clinically significant perioperative cases of actual aspiration, it 
may not be possible to demonstrate statistically that the use of these agents 
actually improves patients' outcomes. In reference to gastric prokinetic 
drugs, antacids, and inhibitors of acid secretion, the ASA task force used the 
same phrasing, “the routine preoperative use of [such medications] … in 
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patients who have no apparent increased risk for pulmonary aspiration is not 
recommended.”  Chemoprophylaxis is only an adjunct to and not a 
substitute for otherwise sound clinical practice
4
. 
 
A. DRUGS TO INCREASE GASTRIC MOTILITY- 
METOCLOPRAMIDE:  
It increases rate of gastric emptying, also an antiemetic which 
increases the lower oesophageal sphincter tone. Metoclopramide increases 
the amount of acetylcholine released at post-ganglionic terminals. It is a 
central dopamine antagonist and raises the threshold of the CTZ. It also 
decreases the sensitivity of the visceral nerves that carry impulses from the 
gut to the emetic centre. It is relatively ineffective in motion sickness and 
other forms of centrally mediated vomiting.  
 
After I.V. administration, it showed an accelerated gastric emptying 
in elective cesasrean section and also in established labour. When prokinetic 
drugs were compared alone with placebo in pregnant women, there was no 
statistically significant difference identified in 'risk of aspiration'
 
although it 
reduces risk of aspiration when combined along with H2 receptor 
antagonists. Adverse effects – Extrapyramidal effects (1%) consist of 
dystonic effects including akathisia, oculogyric crises, trismus, torticollis 
and opisthotonos. 
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B.REDUCTION OF GASTRIC ACIDITY & VOLUME:  
1. Neutralization of secreted gastric acid 
a) Particulate antacids-aluminium & magnesium hydroxide 
b) Non particulate antacid-0.3 molar sodium citrate. 
2. Inhibition of Gastric Acid Secretion  
a. H2-Receptor Blockade 
b. Proton Pump Inhibition 
 
ANTACIDS: 
 
Antacids are mainly divide into particulate and non-particulate 
antacids. Particulate antacids are those containing magnesium or aluminum. 
They are more commonly found to be associated with more severe 
pnemonitis, should aspiration occur. With respect to aspiration prophylaxis, 
clinical use is now confined to non-particulate antacids like 0.3 molar 
sodium citrate. Particulate antacids are commercially freely available and 
they are as effective as sodium citrate in buffering capacity. But, clear 
antacids mix much more effectively with the gastric contents than 
particulate ones
25
. Laboratory evidence in studies
 26 
also indicates that 
particulate antacids can produce significant pulmonary mucosal damage 
when aspirated. 
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H 2 BLOCKERS:  
This group of drugs act by reducing gastric acid secretion by H2 
receptor antagonism. Ranitidine is a highly selective H2 blocker, which 
when given orally, causes a sustained reduction in acid secretion
24
. The 
intravenous mode of administration has been more extensively studied and 
it is found to have a faster onset of action. In emergency general anesthesia 
for ceaserean section, Tripathi et al found all patients had a gastric pH >2.5 
and volume < 25ml by 45min after 50mg of iv ranitidine. Ranitidinre will 
not neutralize the already secreted gastric acid whereas 0.3M sodium citrate 
is effective here. It is also shown that combining 0.3molar sodium citrate 
and iv ranitidine is more effective than ranitidine alone.
 
 
PROTON PUMP INHIBITORS: 
 
In this group of agents, Omeprazole is the drug which is most 
elaborately studied. It is given orally or iv at 40mg, 80mg doses. When 
given orally, omeprazole alone is not as much effective as it is when given 
along with sodium citrate. In setting of emergency LSCS, a single dose iv 
omeprazole 40mg results in same results of pH >2.5 and volume < 25ml as 
like ranitidine. The intravenous formulations of esomeprazole, lanzoprazole 
and pantoprazole have characteristics similar to those of the oral drugs. 
When given to a fasting patient, they inactivate acid pumps that are actively 
secreting. 
31 
 
ANTIEMETICS- 5HT3 RECEPTOR ANTAGONISTS :  
 
They have potent antiemetic properties, mediated through central 5-
HT3-receptor blockade in the vomiting center and chemoreceptor trigger 
zone. They also act by blockade of peripheral 5-HT3 receptors on extrinsic 
intestinal vagal and spinal afferent nerves. Ondansetron, granisetron, and 
dolasetron have a half-life of 4–9 hours, given oral,iv. Palonosetron is a 
newer intravenous agent that has greater affinity for the 5-HT3 receptor and 
a long serum half-life of 40 hours. These drugs are effective in controlling 
PONV (postoperative nausea and vomiting). 
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6. PHARMACOLOGY OF NON-PARTICULATE 
ANTACID- 0.3 MOLAR SODIUM CITRATE 
 
Sodium citrate is considered to be one among the most effective 
medications used for immediate neutralization of the acidic gastric 
contents
26
. Hence, this drug appears to be equally effective in emergency 
and elective cases, done under either regional or general anesthesia
27
.  
 
Mechanism of action and dosage:    
Sodium citrate is the salt of a weak acid. When given orally, it gets 
mixed and combined in the stomach with hydrochloric acid, a strong acid,. 
This reaction produces sodium chloride and citric acid, a weaker acid, which 
acts as a buffer increasing the intragastric pH. 
 
The formulation used in this study is AmbNPA
® 
- available as 30ml 
solution containing sodium citrate IP 500mg, citric acid monohydrate IP 
334mg per 5ml of solution. It is given as single dose of 30ml just 10-20 
minutes prior to induction of anesthesia, is effective in increasing the gastric 
fluid pH above 2.5. There is no „lag time‟ in the onset of action of sodium 
citrate as seen with H2 blockers
22
. 
 
This drug is mainly exerts its effect by acting on the fluid already 
present in the stomach. It has become a reasonable option in emergency 
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situations (assuming patients takes medication orally)
 22
. In addition, they do 
not produce pulmonary damage, should aspiration occur. Its effect usually 
starts immediately after administration, lasting for about 60-180 minutes
2, 26
. 
 
Two studies were done using continuous measurement of intra gastric 
pH in pregnant term woman, which showed the sodium citrate neutralizes 
the gastric acid immediately, but the factor that influences the duration of 
action is the gastric emptying. Sodium citrate in combination with 
effervescent ranitidine cause a rapid increase in gastric pH and maintain the 
pH >2.5 for about 14hr when given orally after induction general 
anesthesia
32
. 
 
Side Effects:  
Citrate when given together along with particulate antacids, increases 
the intestinal absorption of aluminium salts by its reaction with them and 
formation of aluminium citrate.  Aluminium citrate is more absorbable and 
soluble, thus resulting in increased serum concentrations of aluminium. This 
may lead to features of aluminium accumulation such as encephalopathy 
and toxicity, especially in chronic renal failure patients, where there is an 
already existing abnormality in electrolyte handling. 
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Contra indications:  
1. Patients who are advised on sodium restriction in diet.  
2. Severe renal impairment.   
Potassium citrate and citric acid oral solution are contraindicated in 
patients with acute dehydration like diarrhea or vomiting, anuria, 
hyperkalaemia, severe myocardial damage or heat cramps 
 
Special precautions: 
Patients with low urine output leading to aluminium retention, 
congestive cardiac failure, hypertension, renal dysfunction, pulmonary 
oedema, pedal and facial edema or hypertensive disorders and toxaemia of 
pregnancy. 
 
Drug interactions: 
Concurrent usage of antacids with other drugs is common. The scope 
for antacid-drug interaction is mainly dependent upon the physical and 
chemical properties of antacid given. In particulate antacids, the intragastric 
release of free magnesium and aluminum ions has high effects on 
gastrointestinal function and on drug pharmacokinetics. Antacid-drug 
interactions may also occur in accordance with the changes in 
gastrointestinal motility or alterations in gastric acid   pH.   
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Direct adsorption onto the gastric mucosa may cause reduced   
bioavailability of the drug. The clinical evidences in the recent times, would 
suggest that antacids do interact in a remarkable way with certain drugs of 
the cephalosporin, fluoroquinolone, nonsteroidal anti-inflammatory drug 
(NSAID) and group of drugs. Notable interactions are also seen with 
ketoconazole, tetracycline, quinine and glucocorticoids. These interactions 
are taken into serious account in patients with cardiac disease, sepsis, or 
inflammatory syndromes. 
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7. PHARMACOLOGY OF RANITIDINE 
 
Ranitidine reversibly and competitively blocks histamine at H 2 
receptors, particularly those in gastric parietal cells, leading to inhibition of 
gastric acid secretion.  
 
          
 
 
Ranitidine HCl is a white to pale yellow, crystalline substance that is 
soluble in water. It has a slightly bitter taste and sulfurlike odor.  
 
Each tablet, for oral administration, contains 168 mg or 336 mg of 
ranitidine hydrochloride equivalent to 150 mg or 300 mg of ranitidine, 
 
Ranitidine is 50% absorbed after oral administration, compared to an 
intravenous (IV) injection with mean peak levels of 440 to 545 ng/mL 
occurring 2 to 3 hours after a 150 mg dose. Absorption is not significantly 
impaired by the administration of food or antacids. 
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The principal route of excretion is the urine, with approximately 30% 
of the orally administered dose collected in the urine as unchanged drug in 
24 hours.  The elimination half-life is 2.5 to 3 hours 
 
INDICATIONS AND USAGE : 
 Short-term treatment and maintenance therapy of active duodenal 
ulcer. Short-term treatment of active, benign gastric ulcer. Most 
patients heal within 6 weeks. 
 
 Treatment of GERD and endoscopically diagnosed erosive 
esophagitis. Symptomatic relief commonly occurs within 24 hours 
after starting therapy with ranitidine 150 mg bd 
 
 Prophylaxis and treatment of aspiration pneumonitis. 
 
ADVERSE REACTIONS: 
 
Malaise, dizziness, somnolence, insomnia, and vertigo, Constipation, 
diarrhea, nausea/vomiting, abdominal discomfort/ pain, Rare cases of 
hypersensitivity reactions (e.g., bronchospasm, fever, rash, eosinophilia), 
anaphylaxis, angioneurotic edema, and small increases in serum creatinine. 
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DRUG INTERACTIONS AND CONTRAINDICATIONS: 
 
Ranitidine has been reported to bind weakly to cytochrome P-450, 
Increased or decreased prothrombin times have been reported during 
concurrent use of ranitidine and warfarin.  Ranitidine tablets are 
contraindicated for patients known to have hypersensitivity to the drug or 
any of the ingredients. 
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8. PULMONARY ASPIRATION RISK IN OBSTETRIC 
PATIENTS 
 
Mendelson was the first person to describe the entity of pulmonary 
aspiration of gastric contents in obstetric subset of population. He described 
the syndrome in 1946 and the pathogenesis associated with this syndrome
29
. 
He also stressed the importance of perioperative use of anti aspiration 
prophylaxis. 
 
The gastrointestinal system in pregnancy undergoes various changes. 
The stomach is displaced upward toward the left side of the diaphragm 
during pregnancy. The altered position of the stomach tend to alter the 
position of the intraabdominal segment of the esophagus, by displacing it 
into the thorax. This causes a decrease in tone of the lower esophageal high-
pressure zone (LEHPZ), which normally prevents the reflux of gastric 
contents. This displacement of the esophagus also prevents the rise in lower 
esophageal tone that normally accompanies an increase in intragastric 
pressure (IGP)
28
. Progesterone also may contribute to a relaxation of the 
LEHPZ.
28
 The lower esophageal sphincter changes occur as early as in the 
first trimester.  
40 
 
 
 
 
 
 
 
 
 
 
 
The gastric emptying of liquid and solid materials is not altered at any 
time during pregnancy, as evidenced by various methods of evaluation of 
gastric emptying time in pregnant woman as measured by, ultrasound, 
acetaminophen absorption, dyedilution, and radiographic techniques. 
Studies of gastric acid secretion during pregnancy have demonstrated that 
differences in plasma gastrin levels and gastric acid secretion during 
pregnancy are small. 
 
Studies in the nonpregnant and pregnant women of pH and volume of 
gastric contents showed no marked differences in the proportion of women 
who fall under the “at risk” criteria (pH <2.5, volume >25 ml) for 
pulmonary aspiration of gastric contents
29
.  Results of nasogastric aspiration 
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of gastric contents in nonpregnant patients undergoing elective surgery
 
 and 
in pregnant women undergoing elective cesarean section have shown that 
patients who received no preoperative medication that would alter gastric 
volume or pH, approximately 80% of individuals in each group (pregnant 
and nonpregnant) had a gastric pH of 2.5 or less, approximately 50% had 
gastric volumes of 25 mL or greater, and 40% to 50% exhibited both a low 
pH and a volume of at least 25 Ml
29
. 
 
PHARMACOLOGICAL METHODS OF PREVENTING 
ASPIRATION IN PREGNANCY
31
:  
   A)  DURING LABOUR 
 Food and fluids may be taken during labour at the women‟s 
discretion.  
 Fluids only in cases of women at high risk of requiring an operative 
birth.  
 Avoid the use of antacids containing magnesium or aluminium 
(e.g. Mylanta) for symptoms of heartburn or indigestion during 
labour – these medication are associated with severe pneumonitis 
should aspiration occur. 
 Inj. RANITIDINE 50mg IV six hourly for high risk cases as 
selected by anaesthetist in consultation with obstetric staff.  
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An additional dose if it is five hours since last dose when decision for 
operative birth/procedure made.  
  
B) ELECTIVE SURGERY DURING PREGNANCY INCLUDING 
ELECTIVE CAESAREAN SECTION: 
 Either Tab. RANITIDINE 150mg orally the evening prior to surgery 
plus 150mg orally at least one hour pre-operatively on the day of 
surgery.  
 Or Tab. RANITIDINE 300mg orally at least one hour pre-
operatively on the day of surgery. Inj. METOCLOPRAMIDE 10mg 
intravenously one hour pre-operatively. 
 30ml of SODIUM CITRATE mixture orally (0.3 molar solution) 
shall be given 20minutes prior to induction of anaesthesia 
 
C) EMERGENCY OPERATIONS (CAESAREAN, POSTPARTUM 
PROCEDURES etc.)  
Since the risk of aspiration in pregnancy starts from the third trimester 
itself, any emergency procedure during the antenatal period and postpartum 
period should have the following method of acid prophylaxis 
 Inj. RANITIDINE 50mg IV as soon as possible after notification if 
not previously on oral ranitidine.  
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 Inj. METOCLOPRAMIDE 10mg IV as soon as possible after 
notification. 
 30ml of SODIUM CITRATE mixture orally (0.3 molar solution) 
shall be given 20minutes prior to induction of anaesthesia. 
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9. REVIEW OF LITERATURE 
STUDIES RELATED TO ASPIRATION IN THE PERIOPERATIVE 
PERIOD: 
  
1. MENDELSON STUDY: AMERICAN JOURNAL OF 
OBSTETRICS AND GYNAECOLOGY, 1946 
 
In this remarkable study, Curtis Lester Mendelson analyzed and 
presented the remarkable article entitled "Aspiration of gastric contents into 
the lungs under obstetric anaesthesia". He found out aspiration in 66 cases 
out of 43,000 pregnancies. This equals to a notable incidence of about 1 in 
660 pregnancies. Nowadays the occurrence is much lower, but it still 
represents the most common cause of anaesthetic death in pregnant woman.  
 
2. ROBERTS et al 1974:  
He did a pioneering study on the usage of sodium citrate as antacid 
prophylaxis in obstetric subset of patients and arrived at the conclusion that 
it can be a effective regimen when compared with the existing anti-
aspiration pharmacological interventions. Base on their studies, they 
formulated that Volumes of gastric aspirates in excess of 0.3 to 0.4 ml/kg or 
20 to 25 ml may be potentially hazardous sand causes aspiration 
pneumonitis, if inhaled. 
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3. F.M. MESSAHEL, A.S. AL-QAHTANI: PULMONARY 
ASPIRATION OF GASTRIC CONTENTS IN ANESTHESIA: A 
REVIEW OVER 5-YEAR PERIOD - The Internet Journal of 
Anesthesiology. 2009 Volume 19 Number 1. 
This study did an analysis of the incidence, morbidity and mortality 
of pulmonary aspiration during administration of anesthesia in an institute. 
The database of anesthetic related events  were examined to collect the  
details of 12828 patients who were administered  general anesthesia  during 
the 5-year period following application and adoption of stringent guidelines 
for the prevention of  aspiration in the preoperative period.  
 
It included details of patients who got regurgitation and aspiration of 
gastric contents during the course of the anesthetic and in the immediate 
recovery period.  Among this, 451 patients suffered aspiration (3.5% of 
total), out of them 95 (21.1%) were elective and 356 (78.9%) were 
emergency. Out of these, 80 patients (17.7%) aspirated at induction and 371 
(82.3%) at extubation. 
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STUDIES RELATED TO 0.3MOLAR SODIUM CITRATE 
4. SODIUM CITRATE PRETREATMENT IN ELECTIVE 
CESAREAN SECTION PATIENTS- Dewan Dm, Floyd H M, 
Thistle wood J M, Bogard TD , Spielman FJ. 
 
Term pregnant woman, 32 in number who underwent elective 
ceaserean section randomly divided into 3 groups. Group1 got no antacid, 
group 2 -30 ml of 0.3 molar sodium citrate <60mts preoperatively, group 3- 
30 ml of 0.3 molar sodium citrate >60mt preoperatively. Immediately after 
delivery, the stomach was emptied. Mean pH of the gastric aspirate was 
measured in the three groups were 1.8± 2.7, 5.0± 1.5, and 2.7±1.2, 
respectively. Gastric fluid pH was found to be markedly high in group 2, 
compared with other two groups. All patients in group 1, 90% in group 2 
and 50% in group 3 had a gastric pH <2.5. in group 2, none had both pH of 
less than 2.5 and volume > 25 ml. They came to a conclusion that sodium 
citrate effectively rises gastric pH when given < 60 minutes prior to 
induction. 
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5. GASTRIC FLUID pH IN PATIENTS RECEIVING SODIUM 
CITRATE Oscar J. Viegas, MD, Ram S. Ravindran, MD, and Carol 
A. Shumacker, 
In 30 patients undergoing elective surgery, they did an analysis of pH 
of gastric fluid after giving sodium citrate. Following induction of 
anaesthesia & intubation of these patients, the gastric fluid was aspirated 
and the pH was measured. Out of them, 5 persons who had been given 5 ml 
of sodium citrate 5 to 20 minutes before induction of anesthesia were found 
to have a mean pH of 6.2 ± 0.8. In the control group of 5 patients, who did 
not receive sodium citrate had a mean pH of 2.1 ± 1.4. The sodium citrate 
given increases the gastric pH and this would result in decreased pulmonary 
mucosal damage, should aspiration occur. 
  
6. USE OF SINGLE DOSE OF SODIUM CITRATE AS A 
PROPHYLAXIS AGAINST ACID ASPIRATION IN OBSTETRIC 
PATIENTS UNDERGOING CAESAREAN SECTION.  Lim SK, 
Elegbe EO. Med J Malaysia. 1991 : 
The effectiveness of sodium citrate as antacid prophylaxis was 
studied in 3 groups of 20 patients each. Group I (control) received no 
antacid. Group II( elective caesarean section) and Group III (emergency 
caesarean section) were given 30ml of 0.3M sodium citrate immediately 
after their entry into  the operation theatre. The gastric content was aspirated 
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and pH analysis was done just after induction of anaesthesia and at the end 
of surgery before extubating the patient. Sodium citrate was found to 
increase the gastric fluid content pH to much higher range in Group II and 
III patients as compared with the control group.   
 
7. SODIUM CITRATE: AN ALTERNATIVE ANTACID FOR 
PROPHYLAXIS AGAINST ASPIRATION PNEUMONITIS. By J 
Wrobel, T C Koh, J M Saunders Anaesthesia and intensive care 
(1982). 
 
In this study, about 107 general surgical patients who underwent 
elective and emergency procedures were divided into two groups. The test 
group received 5 ml of either sodium citrate 0.3 M and the control got 
placebo 10 minutes before the induction of anesthesia. Gastric contents were 
aspirated soon after induction and intubation and the pH analysis of the 
samples was done. The mean pH of the gastric contents in the sodium citrate 
group was 5.67, and it was 3.21 for those given the placebo it (p less than 
0.001). Of patients who were given sodium citrate 92% had a gastric pH 
above 3.0 when compared with 37% in the placebo group. 
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8. THE EFFECTIVENESS OF SODIUM CITRATE AS AN 
ANTACID- Charles P.Gibbs et al, Anesthesiology 1982 : 
 
26 obstretric patients scheduled for emergency cesarean section were 
given 30 ml of sodium citrate at interval of 10-20 min before induction of 
anesthesia. Two gastric aspirate samples were collected- first sample at 12-
50min after ingestion of antacid and second at 60-180 min. The pH of all 
samples were above 2.5 (mean pH- 5.7 in 1
st
 and 5.2 in 2
nd
 sample). The 
lowest pH were 3.2 and 1.8 respectively. 
 
9. ASPIRATION PROPHYLAXIS FOR PREGNANT PATIENTS 
REQUIRING ANESTHESIA- PUBLISHED NOV 2008.  
 
This article analysed the incidence and various risk factors involving 
the morbidity and mortality from aspiration. It recommends routine 
antiaspiration measures to be taken in all women of >18-20wks gestation, 
and upto 18 hours post partum. It states that particulate antacids when used 
for aspiration prophylaxis causes severe pneumonitis should aspiration 
occur. Sodium citrate 0.3M, 30ml given orally is the most efficient way of 
immediate neutralization of gastric contents- acts within minutes and lasts 
upto 1 hour. The combination of sodium citrate plus ranitidine is even more 
synergistic in reducing gastric acidity. 
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STUDIES RELATED TO COMPARISON OF 0.3MOLAR SODIUM 
CITRATE WITH OTHER DRUGS: 
 
10. EFFECT OF SINGLE DOSE ORAL RANITIDINE AND SODIUM 
CITRATE ON GASTRIC PH DURING AND AFTER GENERAL 
ANESTHESIA (CANADIAN JOURNAL OF ANESTHESIA, 1995, 
PETER ATANASSOFF et al)   
 
In 25 patients scheduled for elective surgery,They analysed the effect 
on gastric pH of the H2 blockers(R) with sodium citrate(SC) as a oral 
effervescent and plain sodium citrate(SC). The drugs were given by 
nasogastric tube placed after induction. A 24hr continuous gastric pH 
monitoring was done by pH electrode. Mean baseline pH were 1.3 in R+SC 
group and 1.2 in plain SC group. These values raised to 6.9(R+SC) and 
4.9(SC) during emergence from anesthesia.. The pH remained above 2.5 for 
14hrs in R+ SC group and for 6hrs in SC group. They concluded that both 
the drugs are effective in neutralizing gastric acid when given orally after 
induction. However, the action of plain SC is shortlived, and if maintenance 
of gastric pH of >2.5 for more than 6hrs is needed, the R + SC combination 
is recommended. 
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11. AN ORAL SODIUM CITRATE- CITRIC ACID NON-
PARTICULATE BUFFER IN HUMANS(J.J.HAUPTFLEISCH 
AND K A PAYNE, BRITISH JOURNAL OF ANESTHESIA 1996) 
 
This study investigated the effect on pH of the gastric pH of single 
dose sodium citrate(antacid) and sodium citrate dehydrate with citric acid 
monohydrate (buffer) in 30 neurosurgical patients for 5-7hrs  duration. A 
control group of 10 received no antacid. The mean baseline pH-  2.64. in 
control group, pH increased to 4.4 at 5hr, returning to beaseline at 7 hr. In 
antacid group, pH raised to 6.11 at 5min and decreased to 3.7 at 7hrs. In 
buffer group, pH was stable at 3.80- 3.95 over 7hr.  
 
12. BICITRA AS AN EFFECTIVE PREOPERATIVE ANTACID by 
Charles. P. Gibbs and Tina et al  :  
 
In this study, the analyzers used Bicitra, a commercially available, 
urine alkanizing solituion which contains the same amount of sodium 
citrate, as that of 0.3 molar sodium citrate. They determined the efficacy of   
Bicitra in elevating the pH of gastric contents above 2.5 in 26 patients 
undergoing ceaserean section in general anesthesia. The pateients were 
given 30ml of Bicitra just before induction, they were rotated side to side 
for the effective mixing of the contents with the antacid. It was found, 
Bicitra increased the pH in 88.5% patients. The buffering capacity (mean 
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pH), as determined with Bicitra is explained is less due to its low pH(4.8) 
Vs 8.5 with 0.3M sod citrate. This is because of the low citric acid content 
of Bicitra. 
 
13. COCHRANE DATA BASE 
This study did   16 meta-analyses on 23 studies that related to 
interventions for reducing aspiration pneumonitis., involving 2658 women 
undergoing cesarean section. The study reviewed the effectiveness of non-
pharmacological interventions and pharmacological drugs which are in 
common practice to reduce aspiration pneumonitis for women who have 
caesarean sections. They measured the primary outcome in terms of  
1. Incidence of morbidity and mortality due to aspiration pneumonitis 
2. Low intragastric pH of less than 2.5, measured after induction of 
anaesthesia. 
3. Increase of intragastric volume of more than 0.4 ml/kg or 25 ml, 
measured after induction of anaesthesia. 
They also analyzed secondary outcomes like: 
1. Incidence of nausea and vomitting during caesarean section or the 
postoperative period.  
2. Intragastric pH above 2.5 and intragastric volume to less than 0.4 
ml/kg measured prior to extubation. 
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They arrived at results suggesting  that while  administering a single 
agent, antacids alone are proposed to have superior efficacy  than H2 
blockers, which are  in turn more efficacious than  proton pump inhibitors 
for increasing gastric pH. The combination of antacids(0.3 molar sodium 
citrate)  plus H2 antagonists(ranitidine)  was shown to be more effective than 
in the patients who had received no  intervention, and  it was a superior 
mode of treatment  to antacids alone in the mode of rising the pH of gastric 
contents. It was also stated that. 
 
The influence of treatments on gastric volume are less analyzed in 
studies and reported. These findings are can be applied for all term 
parturients undergoing caesarean section, especially under general 
anaesthesia. The need of antiaspiration prophylaxis in women undergoing 
caesarean section under regional anaesthesia is a clinical judgement to be 
decided on an individual patient basis. In general these treatments are 
relatively inexpensive and  well tolerated in pregnancy. Hence their routine 
use is  strongly considered in view of the potential benefits,  as aspiration  is 
a cause of maternal mortality, even today. 
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14. GASTRIC FLUID VOLUME AND pH IN ELECTIVE SURGICAL 
PATIENTS: TRIPLE PROPHYLAXIS IS NOT SUPERIOR TO 
RANITIDINE ALONE Maltby JR et al Can J Anaesth. 1990 : 
 
They compared the effect of oral ranitidine given as a sole drug 
against the serial administration of metoclopramide, ranitidine, and sodium 
citrate on gastric aspirate volume and pH in 196 healthy, elective surgical 
patients. Each of the patients were randomly allotted to one of  the four 
groups. Patients in all groups got oral ranitidine 50 mg 2-3 hr before the 
starting of surgery.  
 
Those in Group 1 also received oral metaclopramide 10 mg, about 
one hour before the start of surgery, and sodium citrate 0.3 M 30 ml on 
arrival into the operating area; Group 2 received sodium citrate but no 
metaclopramide; Group 3 received metaclopramide but no sodium citrate. In 
Group 4, the patients received ranitidine drug alone.  
 
In all groups, mean pH was greater than 5.8. Mean aspirate volumes 
were significantly greater in patients who received citrate (Groups 1 and 2- 
it was 22 and 19 ml respectively) than in patients who did not get sod citrate 
(Groups 3 and 4- it was 10ml and 8 ml respectively). Moreover in groups 2 
and 3, one patient each had a gastric aspirate pH of less than 2.5 with 
volume greater than 25 ml. On arrival at these results, they concluded that 
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administration of single ranitidine alone has no greater significant advantage 
than triple prophylaxis with other drugs. 
 
15. ACID ASPIRATION PROPHYLAXIS FOR EMERGENCY 
CAESAREAN SECTION by Stuart Et al, Anaesthesia. 1996: 
 
384 patients requiring emergency Caesarean section under general 
anaesthesia randomly received one of six anti aspiration prophylaxis 
treatments. . They were given drugs-metoclopramide 10 mg, sodium citrate 
administered orally 0.3 M, 30 ml, intravenous administration of ranitidine 
50 mg, omeprazole 40 mg, alone and in various combinations of two of 
these drugs. Compared with sodium citrate alone, the addition of either 
omeprazole ,ranitidine, or metoclopramide alone did not reduce the aspirate  
volume while smaller reduction in gastric volume was seen with the 
addition of metoclopramide and either ranitidine or omeprazole. 
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10. AIM OF THE STUDY 
 
 
The objective of this study is to establish the efficacy of 0.3m sodium 
citrate, a non particulate antacid in neutralizing the secreted gastric acid- as 
prophylaxis against aspiration pneumonitis in obstretic patients undergoing 
elective lower segment cesarean section under general anesthesia. 
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11. MATERIALS AND METHODS 
 
After obtaining approval from the institutional ethical committee of 
Govt. Kilpauk Medical College and Hospital, Chennai-10 and written 
informed consent, fifty term pregnant patients of ASA physical status I & II 
undergoing elective lower segment cesarean section under standardized 
general anesthesia were enrolled in the study. This study was conducted in 
Govt. Kilpauk Medical College and Hospital, Chennai from May 2012- 
August 2012. 
 
STUDY DESIGN: 
Our study was a double- blind prospective randomized control study.  
 
DOUBLE BLINDING TECHNIQUE: 
 The solutions to be administered to the patients were prepared by 
anesthesiology assistant who prepared the solutions in such a way that both 
the solutions are stored in identical amber coloured bottles and labeled 
accordingly. The testing solution, 30ml of 0.3 molar sodium citrate was 
labeled SOLUTION A. The control solution, 30ml of distilled water was 
labeled   SOLUTION B. 
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STUDY PERIOD: 
 The study period was from the time of 30minutes before induction of 
anesthesia up to 2 hours in the postoperative period. 
 
OBSERVATION PERIOD: 
Patients in both the groups were monitored and observed in the 
PACU for 24 hours for any side effects and complications. 
 
STUDY GROUPS: 
 The 50 selected and assessed patients were randomly divided into 
two groups of 25 patients each.  
 
GROUP A -25 patients received 30ml of testing solution A.  
GROUP B-25 patients received 30ml of control solution B, 
 
Both the solutions were kept in identical amber coloured bottles. So, 
neither the patient who is receiving it nor the person giving it, did not know 
what is contained inside the bottle. 
 
The analyzer then allotted them into 2 groups. 25 patients who had 
received 30ml 0.3 molar sodium citrate were assigned to group A or study 
group. Remaining 25 patients who had received 30ml of distilled water were 
allocated to group B or control group. At the end of the surgery, after 
obtaining the gastric aspirate before extubation, all patients in both the 
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groups were given Inj. Ranitidine 50mg i.v. to protect them from the 
aspiration risk. 
 
PATIENT SELECTION: 
All patients 
INCLUSION CRITERIA (OBSTETRIC PATIENTS):  
 pts undergoing elective LSCS under general anesthesia  
 pts fasting for >= 8hrs       
 no use of any other particulate antacids in the preoperative period 
 
EXCLUSION CRITERIA: 
 Patients with BMI > 30 
 patients with anticipated difficult airway   
 patients undergoing emergency surgery     
 h/o any drug use or disease which alters the gastric secretion 
 h/o any drug allergy 
 patient refusal for GA 
 
MATERIALS USED IN OUR STUDY: 
 Testing solution A or control solution B- 30ml in amber color bottles 
 Digital pH meter 
 Nasogastric tube 
 20ml syringe 
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 Xylocaine jelly and adhesive tapes 
 Stethoscope  
 
PARAMETERS OBSERVED IN THE STUDY: 
 Baseline vital parameters- PR, BP, SpO2 
 Baseline pH of gastric aspirate. 
 pH of gastric aspirate – at 30 min following induction 
 pH of gastric aspirate –  before extubation 
 Incidence of nausea and vomiting 
 Incidence of pulmonary aspiration in the post op period 
 Post op vital parameters. 
 
MONITORING: 
STANDARDISED GENERAL ANESTHESIA IN BOTH THE 
GROUPS: 
 observation of baseline vital parameters 
 vital parameters monitoring  
Pulse oximetry 
Non invasive bood pressure 
Electrocardiogram 
End tidal CO2 
Urine output monitoring 
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Temperature monitoring 
 pH measurement by digital pH meter 
 premedication – Inj. Glycopyrrolate 0.2mg iv 
 rapid sequence induction with Inj. Thiopentone and Inj. Succinyl choline 
 cricoid pressure (Sellick‟s manouvere )- released after inflating ET tube 
cuff 
 intubation with 6.5 or 7.0mm cuffed oral ET tube. 
 Maintenance(along with IPPV) – before baby delivery : 50-50 of O2: 
N2O , after baby delivery : 67 % O2 in N2O 
 Reversal of neuromuscular blockade- Inj.Neostigmine & 
Inj.Glycopyrrolate 
 Post op monitoring and observation 
 
CONDUCT OF STUDY: 
Pre operative instructions: 
All term pregnant patients were posted for elective lower segment 
cesarean section, after a complete medical history and examination and a 
proper preoperative assessment. They were explained about this study in 
their own language and written informed consent was obtained from them 
for inclusion into this study. Then, they were taken up for the study, after 
satisfying the inclusion and exclusion criteria.  
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All patients were advised overnight fasting. Patients in both the study 
and control groups received Tab. Ranitidine 300mg on the night before 
surgery. Apart from this, the patients in control group received no other 
non-pharmacological interventions or any form of medications for 
aspiration prophylaxis in the pre- or intra- operative period.  
 
Conduct of standardized general anesthesia : 
On the day of surgery, the patients were shifted to the operating 
theatre. In the premedication room,  all the baseline vital parameters were 
recorded. All patients were premedicated with Inj. Glcopyrrolate 0.2mg just 
before induction. A good intravenous line was established with 18G 
venflon.  
 
A 16 gauge naso gastric tube was introduced gently after thorough 
lubrication and secured, after confirming proper placement in the stomach. 
The gastric aspirate was obtained, and pH of the sample was measured 
using a hand-held pH meter (Hanna HI-96106 Champ pH Tester). It 
was taken as the baseline pH.  Patients in the study group were given 30ml 
of 0.3 molar sodium citrate (Amb NPA) orally, about 20min prior to 
induction of anesthesia. Patients in the control group received 30ml distilled 
water, at around the same period. the study was double blinded since both 
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the patient and the person giving did not know  which solution  was present 
inside the amber coloured bottle. 
 
On shifting the patient to the operating table, routine monitors – pulse 
oximetry, non invasive blood pressure, electrocardiogram, capnography, 
temperature were connected. Patients were explained beforehand, about the 
cricoid pressure that would be given and advised not to get panic. The 
patient was preoxygenated for five minutes with 100% oxygen. During the 
time of induction and intubation, NG tube is pulled out by 10-15cm so that 
the tip of NG tube lies proximal to the lower esophageal sphincter. This is to 
avoid aspiration risk caused by NG tube induced Lower Esophageal 
Sphincter incompetency and also to prevent the regurgitation occuring 
during Inj. Scoline administration. 
 
Patients in both the groups were induced by Rapid Sequence 
Induction using Inj. Thiopentone 3mg/kg. Once the patient loses 
consciousness, the cricoid pressure (sellick‟s manouvere) was applied and 
maintained by a trained personnel. Inj.Succinyl choline 1mg/ kg was given, 
maintaining the cricoid  pressure. They were intubated using 6.5 or 7mm ID 
size endotracheal tube, under direct larnygoscopic vision of the glottis. The 
cricoid pressure was released once the tracheal tube cuff is inflated.                                 
The endotracheal tube was secured after confirming bilateral equal air entry. 
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Following intubation, the NG tube was reinserted to the same level 
and secured. The gastric contents were aspirated at intervals of 5min, 
30min after induction and prior to extubation.  pH of samples were 
analyzed using pH meter. 
 
Anesthesia was maintained with 50%: 50% oxygen and nitrous oxide, 
non-depolarizing muscle relaxant. After delivery of the baby, Inj. 
Pentazoscine , Inj. Syntocinon were given and anesthesia maintained with 
67% nitrous oxide in oxygen. All patients maintained hemodynamic 
stability in the intra operative period.  
 
The gastric aspirate was sampled before extubation and the pH ws 
checked. Before extubation, all patients in both the groups were given Inj. 
Ranitidine 50mg i.v. to protect them from the aspiration risk  
 
The stomach contents were completely emptied before extubation. 
After the patient showed spontaneous breathing efforts, the neuromuscular 
blockade was reversed with Inj.Neostigmine and Inj.Glycopyrrolate 
10µg/kg iv. All patients were extubated on table uneventful, after satisfying 
the extubation criteria.  
 
The NG tube was removed, after applying constant suctioning in the 
recovery room after extubation.The patients were shifted to the recovery 
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room for monitoring for 2hrs.. Then they were moved to post anesthesia 
care unit for further follow up, monitoring and observation for 24 hours. 
During the study period, the following parameters are measured, analyzed 
and compared in the test and control groups. 
1. pH of gastric aspirate – Baseline( before induction of anesthesia) 
2. pH of gastric aspirate – at 5 min after induction 
3. pH of gastric aspirate – at 30 min following induction 
4. pH of gastric aspirate – during extubation 
5. The number of patients who are at high risk of aspiration (based on 
pH of gastric aspirate – Baseline) 
 
STATISTICAL ANALYSIS: 
 It is a randomized  double blind clinical study 
 Variabls were analysed with student „t‟ test and Mann & Whitney „U‟ 
test 
 Sample size obtained according to previous background study. 
 „p‟ value  less than 0.05 was taken as significant. 
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12. OBSERVATION AND RESULTS 
 
Fifty (50)  female patients in ASA I & II who are at term pregnancy, 
undergoing elective lower segment caesarean section under general 
anesthesia were selected for the study. The data & measurements obtained 
from the study were analyzed & tabulated using SPSS. In this study, a „p‟ 
value of less than 0.05 was considered statistically significant and a „p‟ 
value of less than 0.001 was taken as highly statistically significant. 
 
Table: 1 AGE DISTRIBUTION IN STUDY & CONTROL GROUPS 
GROUP 
NO. OF 
PATIENTS 
MEAN 
AGE 
STD. 
DEVIATION 
„P‟ 
VALUE 
STUDY         
(GROUP A) 
25 23.12 2.12 0.537* 
CONTROL          
(GROUP B) 
25 24.78 2.94  
 
*Not Significant (p<0.05) values are express in mean ± SD 
 
The mean age in both the groups was around 25 years. Both the 
groups were comparable with regard to age and there was no statistically 
difference between the two groups. 
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Table: 2   DISTRIBUTION OF AGE-GROUP AMONG GROUPS 
            
 
 
The age group distribution shows more patients in 23-25 age in both 
the study (group A) and control (group B) groups.  
 
 
 
 
 
Age – Groups 
(in years) 
Group – A 
No. of patients (%) 
Group – B 
No. of patients (%) 
20 – 22 11 (43.80) 7 (25.00) 
23 – 25 11 (43.80) 10 (40.60) 
26 -  28 3(12.60) 5 (21.90) 
>28 0 (0) 3 (12.50) 
TOTAL 25 (100.00) 25(100.00) 
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Figure: 1   DISTRIBUTION OF AGE-GROUP AMONG GROUPS 
 
 
 
This graphical representation shows the age group distribution of 
patients in both the groups. 
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Table:  3 BODY WEIGHT IN STUDY AND CONTROL GROUPS 
 
GROUP 
NUMBER 
OF 
PATIENTS 
MEAN 
WEIGHT 
IN KG 
STD. 
DEVIATION 
P VALUE 
STUDY         
(GROUP A) 
25 59.53 11.45 0.950* 
CONTROL          
(GROUP B) 
25 58.75 10.52  
        
*Not Significant (p<0.05) values are express in mean ± SD 
 
The mean weight in both the groups was around 59 kgs. Both the 
groups were comparable with regard to weight. There was no statistical 
difference in between the groups in terms of weight. 
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Table: 4 BODY MASS INDEX IN STUDY AND CONTROL GROUPS 
 
GROUP 
NUMBER 
OF 
PATIENTS 
MEAN 
WEIGHT 
IN KG 
STD. 
DEVIATION 
P VALUE 
STUDY         
(GROUP A) 
25 24.34 2.38 0.572 
CONTROL          
(GROUP B) 
25 27.18 2.98  
 
*Not Significant (p<0.05)  
The values are expressed in mean ± SD 
 
The mean Body Mass Index was around 25. There was no statistical 
difference in between the groups in terms of BMI. 
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FIGURE :2 DISTRIBUTION OF INDICATIONS FOR LSCS IN TWO 
GROUPS 
 
 
                                
 
 
 
 
 
 
 
 
 
 
 
 
In this column diagram, the indications for which the patients 
underwent ceaserean section are shown. The other causes- post dated 
pregnancy, precious pregnancy etc.  
 
 
A – Previous LSCS 
B – Primi with CPD 
C – Other causes 
     A     B    C 
GROUP – A 
GROUP - B 
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Table: 5 FASTING DURATION IN STUDY AND CONTROL 
GROUPS 
 
This table compares the fasting duration (in hours) in the pre 
operative period, which is almost the same – 9 hours in both the groups.  
 
  
 
 
     
 
GROUP 
NUMBER 
OF 
PATIENTS 
MEAN 
FASTING 
TIME(HRS) 
STD. 
DEVIATION 
P VALUE 
STUDY         
(GROUP 
A) 
25 9.41 0.76 0.589 
CONTROL          
(GROUP 
B) 
25 9.06 0.84  
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Table: 6 MEAN pH VALUES AT VARIOUS INTERVALS IN THE 
STUDY AND CONTROL GROUPS 
            
The values are expressed in mean ± SD. 
       The mean baseline pH in study and control groups are 2.94 and 2.84 
respectively and there is no statistical difference in baseline pH values  in 
both. After administration of the test solution, the pH values in the study 
group at 5min, 30min and extubation are all at a higher range than that of 
control group, signifying the acid neutralizing effect of 0.3M sodium citrate 
in the study group. 
VARIABLES 
 
STUDY  
(GROUP A) 
CONTROL 
(GROUP B) 
                               
Baseline pH 
     
    2.94 ± 0.76 
         
    2.84 ± 0.73 
 
pH after 5 mins. 
 
4.46 ± 1.05 
 
2.97 ± 0.73 
 
pH after 30 mins. 
 
4.53 ± 1.11 
 
2.86 ± 0.72 
 
pH  before Extubation  
 
4.64 ± 1.20 
 
2.77 ± 0.67 
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Table: 7 COMPARISON OF BASELINE pH BETWEEN                       
TWO GROUPS 
Groups 
Mean 
baseline 
pH 
Mean 
Rank 
Sum of 
Ranks 
Mann-Whitney U 
test value & p - 
value 
STUDY 
(GROUP A) 
 
2.94 
33.88 1084.00 
468.00 
0.554 
NS 
CONTROL 
(GROUP B) 
 
2.84 
31.12 996.00 
 
NS - statistically not significant 
 
The base line pH taken in both the groups before giving the test drug, 
before induction, was comparable in both the groups. The mean rank was 
around 32.  There was no statistical significance in between the two mean 
pH, since „p‟ value is more than 0.05. 
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Table: 8 COMPARISON OF pH AT 5MIN OF INDUCTION 
BETWEEN TWO GROUPS 
 
HS: Highly Statistically Significant 
 
The table 8 shown compares the pH values at 5 min after induction, 
after the test drug is given in the study and control groups. A highly 
statistical difference was observed in between the groups. This implies that 
sodium citrate increases the pH of the gastric contents well above than the 
pH in control group. 
Groups 
Mean pH 
at 5min 
Mean 
Rank 
Sum of 
Ranks 
Mann-Whitney U 
test value & p - 
value 
STUDY 
(GROUP A) 
4.46 44.75 1432.00 120.00 
0.000 
HS CONTROL          
(GROUP B) 
2.97 20.25 648.00 
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Table: 9 COMPARISON OF pH AT 30 MIN OF INDUCTION 
BETWEEN TWO GROUPS 
 
 
 
 
 
 
 
 
 
HS : Highly Statistically Significant 
 
In table 9, the pH in the study group is higher than in the control 
group, as seen by the difference in mean ranks in both the groups.  A „p‟ 
value of <0.001 is observed in this table, implying high statistical difference 
in pH between the groups. 
 
Groups 
Mean pH 
at 30min 
Mean 
Rank 
Sum of 
Ranks 
 
Mann-Whitney U 
test value &           
p - value 
STUDY 
(GROUP A) 
4.53 45.44 1454.00 98.00 
0.000 
HS CONTROL          
(GROUP B) 
2.86 19.56 626.00 
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TABLE: 10 COMPARISON OF pH AT EXTUBATION BETWEEN 
TWO GROUPS 
 
 
 
HS : Highly Statistically Significant 
 
Table 10 shows the pH measured at extubation, which also states a 
high statistically significant difference in the pH between the groups, as 
seen in the mean rank and „p‟ value. 
 
 
Groups 
Mean pH at 
extubation 
Mean 
Rank 
Sum of 
Ranks 
Mann-Whitney U 
test value &              
p - value 
STUDY 
(GROUP A) 
4.64 45.78 1465.00 87.00 
0.000 
HS CONTROL          
(GROUP B) 
2.77 19.22 624.00 
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Table: 11   PATIENTS AT HIGH RISK (pH < 2.5) AT VARIOUS 
INTERVALS: 
SAMPLING INTERVALS 
STUDY 
GROUP – A 
(N = 25) 
CONTROL 
GROUP – B 
(N = 25) 
Baseline 11 (44 %) 11 (44%) 
5 minutes after induction 0 (0) 10 (40%) 
30 minutes after induction 0 (0) 9 (36%) 
Extubation 0 (0) 11 (44%) 
 
 
Table 11 shows the number patients who are having a pH of less than 
2.5 in both the groups at various time intervals after induction and at 
extubation. They in turn fall under the high risk category for pulmonary 
damage if aspiration occurs, as per criteria. From this table, it is evident that, 
no patient in the study group came under high risk, after the drug  is given.  
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Figure: 3 DISTRIBUTION OF PATIENTS AT HIGH RISK (pH < 2.5) 
AT VARIOUS TIMING 
 
 
 
FIGURE 3 is the pictorial representation of table 11. This also shows 
no patient is in high risk in the study group. 
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Table : 12 DISTRIBUTION OF TIME AT WHICH pH  WAS 
MAXIMUM IN STUDY AND CONTROL GROUPS 
 
Various Timing Group – A Group - B 
5 min                  
after induction 
6.8 4.5 
30 min after 
induction 
6.7 4.6 
Extubation 6.4 4.3 
                                                                                                                                         
         
Table 12 helps to find out the maximum highest pH attained in the 
two groups at various time intervals. It is obvious that the highest pH of 
study group, A is higher than the pH in the control group at all times. In the 
study group A itself, the5min pH value is the highest. This signifies the 
protective effect of sodium citrate is maximal in about 30min after 
administration, offering lower risk of pulmonary damage, should aspiration 
occur during intubation. The figure 4 also mentions the same.  
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FIGURE: 4 DISTRIBUTION OF TIME AT WHICH pH WAS 
MAXIMUM IN STUDY AND CONTROL GROUPS 
 
 
This graphical representation shows that the maximum mean pH in 
the study group A is 6.8 at the time of 5 min after intubation, than in the 
control group B.    
 
  
GROUP - A  
GROUP - B  
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Table 13: DISTRIBUTION OF RANGE OF pH AT VARIOUS TIME 
PERIOD AMONG STUDY (GROUP A)  
 
 
In table 10, maximum number of patients have a pH range between 
3.1- 5.0 at all times, well above the high risk (pH of less than 2.5). The pie-
chart in figure 5 denotes the same. 
RANGE OF pH 
STUDY GROUP A ( N=25 ) 
5 MIN 
AFTER 
INDUCTION 
30 MIN 
AFTER 
INDUCTION 
EXTUBATION 
< 2.5 0(0.00) 0(0.00) 0(0.00) 
2.6 – 3.0 2(8%) 1(4%) 3(12%) 
3.1 – 4.0 9(36%) 7(28%) 8(32%) 
4.1 – 5.0 7(28%) 7(28%) 6(24%) 
5.1 – 6.0 4(16%) 6(24%) 4(16%) 
6.1 – 7.0 3(12%) 4(16%) 4(16%) 
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FIGURE 5 : DISTRIBUTION OF pH IN  STUDY GROUP A
 
FIGURE 5A- DISTRIBUTION OF pH AT 5 MIN 
                                                                  
 
FIGURE 5B- DISTRIBUTION OF pH AT 30 MIN 
 
FIGURE 5C - DISTRIBUTION OF pH AT EXTUBATION 
< 2.5 
 2.6-3.0 
3.1-4.0 
 
4.1-5.0 
 
5.1-6.0 
 
6.1-7.0 
pH RANGE 
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Table: 14 DISTRIBUTION OF RANGE OF pH AT VARIOUS TIME 
PERIOD AMONG CONTROL (GROUP B) 
 
In table 14, pH in the control group shows more number of patients 
having pH in the range of 2.1-3.0, which in turn comes under the high risk 
category. No patient in control group had a gastric pH of more than 5.1. The 
pie chart in figure 6 also shows the distribution of pH in control group, 
depicting the same. 
 
 
RANGE OF pH 
GROUP - B  ( N=25 ) 
 5 MIN 30 MIN EXTUBATION 
< 2.5 10(40%) 9(36%) 11(44%) 
2.6 – 3.0 5(48%) 8(62%) 6(52%) 
3.1 – 4.0 8(32%) 6(24%) 7(28%) 
4.1 – 5.0 2(8%) 2(8%) 1(4%) 
5.1-6.0 0(0) 0(0) 0(0) 
6.1- 7.0 0(0) 0(0) 0(0) 
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FIGURE 6 : DISTRIBUTION OF pH IN THE  CONTROL GROUP B 
 
FIGURE 6A: DISTRIBUTION OF pH AT 5 MIN OF INDUCTION 
                                                                                                  
FIGURE 6B: DISTRIBUTION OF pH AT 30 MIN OF INDUCTION 
 
       FIGURE 6C: DISTRIBUTION OF pH AT EXTUBATION 
< 2.5 
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3.1-4.0 
 
4.1-5.0 
 
5.1-6.0 
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13. DISCUSSION 
 
Based on the observation and results obtained in our study involving 
25 patients in each group are discussed in detail by comparing with the 
available evidence in the literature. 
 
In our study comparing the efficacy of 0.3 molar sodium citrate, a non 
particulate antacid with control group, the mean age, weight, Body Mass 
Index were comparable among the two groups(Tables 1,2,3,4 ). Our results 
show that 0.3M sodium citrate is effective as a form of anti-aspiration 
prophylaxis by increasing the pH of gastric contents than that of the control 
group. It in turn lessens the degree of damage to pulmonary mucosa, if 
aspiration of this less acidic gastric content occurs. 
 
0.3 molar sodium citrate, 30ml when given in 20min before 
induction, raises the pH of gastric contents to above 2.5, in the protective 
range. The study group chosen was pregnant women undergoing elective 
LSCS. This type of patients are considered to be „full stomach‟ even after 
they are allowed adequate proper fasting time in the preoperative period. 
Hence, they are always at a greater risk of aspiration during the peripartum 
period. Procedures under general anesthesia in this group carries even more 
higher risk, especially during times of intubation and extubation.  
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The dosage of sodium citrate was 30ml. In his study, Lahiri et al. 
found that 5 ml of 0.3 molar sodium citrate increased th gastric pH above 
3.0 in 21 of 22 parturients. Later, Heath and Hester, analyzed the same 
volume and dosage of sodium citrate and they found no difference was there 
in between treated and untreated groups. In the subsequent related studies, 
they increased the volume of sodium citrate given to twice, and the 
buffering capacity of antacid administered, and successfully brought the 
gastric content ph to above 2.5. In our study also, 30ml was used to increase 
the pH.  
 
The timing of drug before is also accountable, since in their study, 
DEWAN ET AL showed that the elevated mean ph in the short interval 
group (sodium citrate given in less than 60min before induction) and the 
increased incidence of low pH in the long interval group (sodium citrate 
given in more than 60min before induction), when compared to the short 
interval group, is due to the shorter duration of action of sodium citrate. In 
our study, the mean timing of drug administration was 20 minutes (less than 
half an hour) before induction. 
 
Recently, O'Sullivan and Bullingham observed that gastric emptying 
represents an important factor in determining the duration of action of 
antacids (14). When gastric emptying occurs faster, the antacid rapidly 
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leaves the stomach and this results in a short duration of action. Factors that 
slow gastric emptying cause extended duration of action of antacids. Our 
patients received narcotics in the intraop period   that might slow gastric 
emptying. 
 
The sampling interval was standardized in both the groups to find out 
the time at which the drug action in elevating the gastric pH was maximal. 
In our study, it was noted that ph elevation was maximal 6.8 in drug group 
(table 10) during the time of intubation. Thus, it offers higher protection at 
that time. 
 
As per Roberts and Shirley risk criteria, no patients given sodium 
citrate had a pH of less than 2.5 at any point of time during subsequent 
samplings (table 9). This correlates well with the study done by Oscar and 
Ravindran et al, where it was noted that nearly all patients given sodium 
citrate had a gastric pH of more than 3.5, whereas in the control group only 
two patients (13 %) had the pH above 2.5. 
 
In our study, volume of gastric contents was not measured as it was 
not considered as a parameter for comparison between the two groups. The 
influence of gastric volume by antacids have been described in the 
literature. An increased incidence of gastric volumes more than 20 ml after 
the administration of antacids has been found in study of in                      
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Stoelting R K et al. However, other reports (Detemir M D et al, Newson A J 
et al ) found that the dosing of antacid does not affect the mean volume of 
gastric contents.  
 
Most commercial preparations has aluminum hydroxide which may 
slow down the gastric emptying and therefore produce larger gastric 
volumes ((Detemir M D et al). The estimation of gastric fluid volume by 
aspiration of the stomach is less than ideal and may reflect an erroneously 
low measurement, as full aspiration of all the gastric contents is not possible 
even after repositioning and aspirating. Hence, the measurement of gastric 
fluid volume is imprecise. So, in our study we elected not to measure gastric 
volume in both the group of patients. 
 
Moreover, as stated before, the critical volume and pH of gastric 
contents needs to be revised as per the pioneering studies by Rocke DA et 
al. this will make clinicians towards a more liberal use of antacids, which 
are mainly avoided because of their inherent propery of increasing the 
gastric content volume to above the critical limit. 
 
The pH meter used for analyzing pH in our study, is a pen type pH 
meter.  Hence, the pH can be measured at the patient‟s bedside, which is 
more time conserving and economical. The amount of aspirate required for 
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each sample is also less than 20ml when compared with the conventional 
laboratory techniques requiring 50-60ml of aspirate for analysis. 
 
The side effects and drug interaction of sodium citrate as discussed in 
the literature was seldom seen in our study. This may be due to the reason 
that all patients were well scrutinized in the preoperative for co-existing 
medical illness and drug intake that interact with sodium citrate. 
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14. SUMMARY 
 
A prospective randomized double blind study was designed to 
establish the efficacy of 0.3molar sodium citrate in pregnant patients 
undergoing elective lower segment caesarean section under general 
anesthesia. Based on the analysis of the results and discussion in our study, 
the conclusions arrived at are summarized as below. 
In our study,  
 The demographic variables such as age, height, weight & body mass 
are comparable between the groups 
 The preoperative fasting time was around 9 hours, which is also 
comparable in both the groups. 
 We observed that the baseline pH was > 2.5 and were comparable 
with no significant difference between the study and control groups. 
 The mean pH measured at 5 minutes, 30 minutes and extubation in 
study group was statistically significantly higher in the study group 
than in the control group. ( p value < 0.001- highly significant ). 
 The mean pH in the study group was maximally highest at 5min after 
intubation, signifying the protective effect of 0.3M sodium citrate 
during the time of induction, laryngoscopy and intubation. 
  No patient were at high risk zone (i.e pH <2.5) in the study and 
control groups, at any time during the anesthesia. 
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 No patients were observed to have complications like aspiration, 
nausea or vomiting in the intra operative or postoperative period. 
 The side effects of general anesthesia like nausea, vomiting, 
epigastric pain was found in few of our patients in both the groups 
with not much statistical significance in our study. 
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15. CONCLUSION 
 
We conclude that the non particulate antacid 0.3 molar sodium citrate 
given orally about 20min before induction of anesthesia, is an effective and 
safe antacid for anti-aspiration prophylaxis in all elective obstetric surgeries 
without producing any side effects.  
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17. ANNEXURES 
PROFORMA 
Name of patient  : 
Group assigned  : 
Age / Sex   : 
IP number   : 
Weight/ height  : 
Preop assessment 
         History- 
         Examination- 
        Airway assessment- 
        Diagnosis and indication for LSCS- 
         ASA status – 
Last oral intake  : 
Premedication  : 
Test solution number : 
Time of drug administration before induction  : 
Duration of surgery  : 
Baseline pH            : 
pH at 5min   :                         pH at 30min :                        pH at extubation: 
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ETHICAL COMMITTEE CERTIFICATE 
100 
 
PATIENT CONSENT FORM 
 
“A Study To Determine The Efficacy Of 0.3 M Sodium Citrate As 
An Antacid Prophylaxis Against Aspiration Pneumonitis In Obstetrical 
Patients Undergoing Elective Ceasarean Section Under General 
Anesthesia” 
 
Study centre: Department of Anaesthesiology & Critical Care, Kilpauk. 
Medical college: 
Participant name:   Age:    Sex: 
I.P. no: 
 
I, confirm that I have understood the purpose of procedure for the 
above study. I had the opportunity to ask the question and all my questions 
and doubts have been answered to my satisfaction. 
 
I have been explained about the pitfall in the procedure and the 
management of it. I have been explained about the safety, advantages and 
disadvantages of the techniques. 
 
I understand that my participation in the study is voluntary and that I 
am free to withdraw at anytime without giving any reason. 
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I understand that investigator, regulatory authorities and the ethics 
committee will not need my permission to look at my health records both in 
respect to current study and any further research that may be conducted in 
relation to it, even if I withdraw from the study. 
 
I understand that my identity will not be revealed in any information 
released to third parties or published, unless as required under the law. I 
agree not to restrict the use of any data or results that arise from the study. 
 
I hereby consent to participate in this study of “A Study To 
Determine The Efficacy Of 0.3M Sodium Citrate As An Antacid 
Prophylaxis Against Aspiration Pneumonitis In Obstetrical Patients 
Undergoing Elective Caesarian Section Under General Anesthesia”. 
 
 
Name of the patient:  Signature/thumb impression of patient:   
Name of the witness:  Signature: 
Address:    Contact Number: 
Name of the investigator:  Signature: 
Time:     Date: 
Place:           
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MASTER CHART – STUDY GROUP - A 
S.NO NAME AGE/SEX 
WT. 
(KG) 
IP NO DRUG DIAGNOSIS 
FASTING 
(HRS) 
BASELINE 
PH 
PH 
5MIN 
PH 30    
MIN 
PH 
EXTUB 
1 INBASELVI 25/F 80 13140 
NA 
CITRATE PREV LSCS &CPD 10 4.3 3.1 5.2 5.8 
2 NIRMALA 24/F 90 10517 NA CIT PRIMI WITH CPD 9 2.2 3.8 5.2 5.1 
3 SHOBANA 26/F 74 11863 NA CIT PREV LSCS &CPD 10 2.2 5.8 6.1 6 
4 JAMUNA 24/F 82 17062 NA CIT PRIMI -POSTDATED  PREG 10 4.3 6.2 6.7 6.1 
5 UMA 25/F 75 13415 NA CIT PRIMI WITH CPD 8 2 5.8 4.2 6.4 
6 KANIMOZHI 22/F 55 10338 NA CIT PREV LSCS &CPD 10 1.9 4.8 5.2 5.3 
7 SIVASAKTHI 25/F 56 14087 NA CIT PREV LSCS &CPD 10 2.1 6.8 5.8 3.1 
8 REVATHY 26/F 47 14090 NA CIT PRIMI- PRECIOUS  PREG 10 3.8 5.2 6.4 6.2 
9 KUMUDHA 20/F 50 18140 NA CIT PRIMI WITH CPD 8 3.2 4.1 4.3 3.8 
10 PAULIN 21/F 45 18121 NA CIT PREV LSCS 10 4.2 4.5 4.6 4.2 
11 SAMUNDEESWARI 20/F 55 17853 NA CIT PRIMI-POSTDATED PREG 9 3 3.6 4.5 4.6 
12 LATHA 21/F 50 16812 NA CIT PREV LSCS &CPD 10 4.3 6.2 6.3 2.8 
13 KAMALA DEVI 25/F 62 17179 NA CIT PREV LSCS &CPD 8 3.1 4.8 5.1 5.2 
14 JHANSI RANI 21/F 65 17233 NA CIT PRIMI WITH CPD 10 2.3 3 3.2 3.3 
15 JAYANTHI 22/F 45 17423 NA CIT PREV LSCS 10 3.2 5 5.1 4.9 
16 KOMALA 23/F 60 17942 NA CIT PREV 2 LSCS 9 1.8 2.6 2.7 3 
17 AROKIA MARY 22/F 54 17899 NA CIT PRIMI WITH CPD 8 2.3 3.8 3.8 3.7 
18 SHAGIRA BEGUM 20/F 65 20045 NA CIT PREV LSCS 10 2.4 3.2 3.3 3.6 
19 REKHA 26/F 66 20076 NA CIT PRIMI WITH CPD 9 2.4 3.2 3.3 3.4 
20 PUSHPA 21/F 45 20013 NA CIT PREV LSCS 10 2.8 3.9 4.1 4.3 
21 DURGA DEVI 24/F 68 18426 NA CIT PRIMI WITH CPD 10 4.1 5.2 3.8 2.8 
22 PACHAIAMMAL 22/F 50 20043 NA CIT PREV LSCS 9 2.3 3.8 3.2 3.6 
23 MARY 24/F 48 19986 NA CIT PREV 2 LSCS 10 2.8 3.8 3.6 3.6 
24 ALLIRANI 24/F 56 18453 NA CIT PREV LSCS 10 3.5 4.6 4.7 4.8 
25 SATHYA 23/F 58 20527 NACIT PREV LSCS 8 3.1 4.6 4.3 4.2 
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MASTER CHART – CONTROL GROUP - B 
S. 
NO 
NAME AGE SEX 
WT 
(KG) 
IP NO DRUG DIAGNOSIS FASTING 
BASELINE 
PH 
PH 
5MIN 
PH 
30 
min 
PH 
EXTUB 
1 NANDHINI 22/F 62 10517 PLACEBO PREV LSCS 9 HR S 2.6 2.8 2.6 3.1 
2 MALLIGA 26/F 65 11223 PLACEBO PRIMI WITH CPD 9 HRS 2.1 2.1 2.4 2.5 
3 KANNAKI 28/F 56 10113 PLACEBO PREV LSCS 10 HRS 2.5 2.8 2.5 2.6 
4 KALAISELVI 21/F 55 18103 PLACEBO PRIMI WITH CPD 8 HRS 3.2 3.3 2.8 2.8 
5 SUBHA 24/F 60 16800 PLACEBO PREV LSCS 10 HRS 2.9 3.1 2.6 2.6 
6 DHANALAKSHMI 21/F 45 16870 PLACEBO PRIMI- POSTDATED PREG 9 HRS 3.2 3.4 3.1 2.7 
7 SARALA 24/F 55 17176 PLACEBO PRIMI WITH CPD 8 HRS 1.7 2 1.6 1.7 
8 KAVITHA 25/F 70 17236 PLACEBO PREV LSCS 10 HRS 2.1 2.2 2.4 1.9 
9 NASEEMA 24/F 68 18423 PLACEBO PREV LSCS 7 HRS 3.4 2.9 3 3.1 
10 DEVIKA DEVI 27/F 60 18446 PLACEBO PRIMI WITH CPD 10 HRS 2.7 2.8 2.3 2.3 
11 AMUL 21/F 48 18502 PLACEBO PREV LSCS 8 HRS 4.2 4.5 4.5 3.9 
12 KANCHANA 23/F 80 18842 PLACEBO PREV LSCS 9 HRS 2.6 2.7 3 2.5 
13 SHAKILA BANU 23/F 75 18823 PLACEBO PRIMI -POSTDATED PREG 10 HRS 2.3 1.8 1.8 2 
14 MUTHU SELVI 30/F 70 18876 PLACEBO PRECIOUS PREGNANCY 9 HRS 2.8 3.1 2.8 2.6 
15 LALITHA 28/F 68 19277 PLACEBO PREV LSCS 8HRS 2.2 2.4 2.3 2.3 
16 NATHIYA 22/F 53 19677 PLACEBO PRIMI WITH CPD 10 HRS 3.1 3.5 3.4 3 
17 MARIAMMAL 29/F 55 19740 PLACEBO PREV LSCS 9 HRS 4.2 4.5 4.6 4.3 
18 BAGHYALAKSHMI 24/F 65 19233 PLACEBO PREV LSCS WITH CPD 8 HRS 2.4 3.1 3.2 3.3 
19 ANNAL 32/F 67 19824 PLACEBO PREV LSCS 10 HRS 2.7 2.9 2.7 2.3 
20 DEVI 24/F 55 19199 PLACEBO PRIMI- POSTDATED PREG 9 HRS 2.1 2.4 2.3 2.3 
21 INBASEELI 28/F 45 12537 PLACEBO PRIMI-SHORT STATURE 10 HRS 2.8 2.7 2.8 2.6 
22 SUDHA 26/F 59 19124 PLACEBO PREV LSCS 9 HRS 2.2 2.4 2.6 2.1 
23 RAJESWARI 29/F 65 19599 PLACEBO PREV LSCS 10 HRS 3.9 3.8 3.5 3.6 
24 DEVAKI 24/F 56 19604 PLACEBO PRIMI  WITH CPD 9 HRS 3.4 3.2 2.8 2.5 
25 INDIRA 22/F 55 20807 PLACEBO PRIMI WITH MOBILE HEAD 8 HRS 2.8 3.9 4.2 4.3 
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